Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lercanidipine
Drug ID BADD_D01255
Description Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Indications and Usage For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Marketing Status approved; investigational
ATC Code C08CA13
DrugBank ID DB00528
KEGG ID D08111
MeSH ID C060343
PubChem ID 65866
TTD Drug ID D0P6ZH
NDC Product Code Not Available
UNII V7XTJ4R0BH
Synonyms lercanidipine | methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | lercanidipine hydrochloride | Zanidip | Lerdip | Lercadip | REC 15-2375 | REC-15-2375
Chemical Information
Molecular Formula C36H41N3O6
CAS Registry Number 100427-26-7
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+ ](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diabetes mellitus05.06.01.001; 14.06.01.001---
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dizziness postural02.11.04.008; 17.02.05.004; 24.06.02.008---
Dry mouth07.06.01.002--
Dry throat07.06.01.005; 22.12.03.005---
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Ear disorder04.03.01.001---
Eosinophilic pneumonia01.02.04.003; 22.01.01.004---
Erythema23.03.06.001---
Erythema multiforme10.01.03.015; 23.03.01.003--
Eye disorder06.08.03.001---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Feeling hot08.01.09.009---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Gamma-glutamyltransferase increased13.03.04.024--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Gingival hypertrophy07.09.13.008---
Glossitis07.14.01.001---
Gynaecomastia05.05.02.003; 21.05.04.003--
Haemoglobin decreased13.01.05.003---
Headache17.14.01.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages